Table 2 Progression-Free Survival (PFS) data for somatic versus germline BRCA mutations
Study Name | PFS for somatic BRCA | PFS for germline BRCA | Statistical difference between somatic versus germline |
|---|---|---|---|
ARIEL3 [21] | HR of 0.23 (0.10–0.54) compared to placebo, Median PFS 15.7 months | HR of 0.25 (0.16–0.39 germline) compared to placebo, Median PFS 24 months | Not provided |
ENGOT 0 V16/NOVA [33] | HR of 0.27 compared to placebo | HR of 0.27 compared to placebo | Not provided |
STUDY 19 [23] | HR of 0.23 (0.04 to 1.12) versus placebo, 3/10 progression events | HR of 0.17 (0.09 to 0.34) versus placebo, 16/49 progression events | Not provided |
V. Rodriguez-Freixinos et al. [37] | Absolute value not reported | Absolute value not reported | HR of 0.75 for PFS (0.4–1.41) between somatic versus germline, p = 0.38 |
Labidy-Galy et al. [27] | 6.8 months (5.1-NA) Median PFS | 16.3 (10.4–19.8) median PFS | HR of 1.4 (0.5–3.9), p = 0.52 |